The Board of Directors of Panacea Biotec Limited has approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The company reported a total income from operations of ₹16,675 Lakh for the consolidated quarter ended March 31, 2026, compared to ₹16,519 Lakh in the previous quarter and ₹13,253 Lakh in the corresponding quarter of the previous year. The net loss after tax for the consolidated quarter ended March 31, 2026, stood at ₹100 Lakh, compared to a profit of ₹389 Lakh in the previous quarter and a loss of ₹199 Lakh in the corresponding quarter of the last year.

Panacea Biotec is an innovation-led, biotechnology company with strong research and manufacturing capabilities. The company focuses on areas including vaccines, diabetes management, and pain management. Recent updates from 2025 include the company completing the enrollment of study participants for its DengiAll Phase-III clinical trial, with the vaccine expected to enter markets by 2027 pending regulatory approvals. Furthermore, in July 2025, the company entered into a settlement agreement with Apotex Inc., USA, to resolve an ongoing dispute.